Skip to main content

Propranolol (Monograph)

Brand names: Inderal LA, Innopran XL
Drug class: alpha-Adrenergic Blocking Agents

Medically reviewed by Drugs.com on Apr 10, 2024. Written by ASHP.

Introduction

Nonselective β-adrenergic blocking agent (β-blocker).b c

Uses for Propranolol

Hypertension

Management of hypertension, alone or in combination with other antihypertensive agents.201 314 323 1200 b c Not indicated for the treatment of hypertensive emergencies.b c

β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).353 501 502 503 504 515 523 524 527 800 1200 Propranolol is one of several β-blockers (including bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, and timolol) recommended by a 2017 ACC/AHA multidisciplinary hypertension guideline as first-line therapy for hypertension in patients with stable ischemic heart disease/angina.1200

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.1200 1220 1229

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at a BP of ≥130/80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.330 336 337 501 504 1200 However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.500

Chronic Stable Angina

Long-term management of chronic stable angina pectoris.602

β-Blockers are recommended as first-line anti-ischemic drugs in most patients with chronic stable angina; despite differences in cardioselectivity, intrinsic sympathomimetic activity, and other clinical factors, all β-blockers appear to be equally effective for this use.1101

Supraventricular Arrhythmias

Treatment of supraventricular tachycardia (SVT) (e.g., atrial flutter, junctional tachycardia, focal atrial tachycardia, paroxysmal supraventricular tachycardia [PSVT]).201 338 401 700 701

Vagal maneuvers and/or IV adenosine are considered first-line interventions for acute treatment of SVT when clinically indicated; if such measures are ineffective or not feasible, may consider an IV β-blocker.700 Oral β-blockers may be used for ongoing management.700 Although evidence of efficacy is limited, experts state that overall safety of β-blockers warrants use.700

Used to slow ventricular rate in patients with atrial fibrillation or flutter when ventricular rate cannot be controlled by standard measures.201 338 701

Ventricular Arrhythmias

Generally less effective in the management of ventricular arrhythmias than supraventricular arrhythmias, but may be considered when cardioversion or other drugs not effective.338

May be used in the treatment of persistent premature ventricular complexes.338

β-Blockers have been used in patients with cardiac arrest precipitated by ventricular fibrillation† [off-label] or pulseless VT† [off-label]; however, routine administration after cardiac arrest is potentially harmful and not recommended.400

β-Blockers may be useful in the management of certain forms of polymorphic VT† [off-label] (e.g., associated with acute ischemia).401

Tachyarrhythmias Associated with Cardiac Glycoside Intoxication or Catecholamine Excess

Management of supraventricular or ventricular tachyarrhythmias associated with cardiac glycoside toxicity when AV block is not present.b

Management of resistant tachyarrhythmias associated with catecholamine excess during anesthesia; use with extreme caution and constant ECG and central venous pressure monitoring.a b More effective and less hazardous therapy, such as lessening the depth of anesthesia or improving ventilation, is preferred.a

Hypertrophic Subaortic Stenosis

Management of exertional or other stress-induced angina, vertigo, syncope, and palpitation in patients with hypertrophic subaortic stenosis; clinical improvement may be temporary.b

Pheochromocytoma

Management of symptoms resulting from excessive β-receptor stimulation in patients with inoperable or metastatic pheochromocytoma, as an adjunct to α-adrenergic blocking agents.b Initiate therapy with an α-adrenergic blocking agent prior to treatment of pheochromocytoma.b (See Pheochromocytoma under Cautions.)

Management of tachycardia prior to or during surgery in patients with pheochromocytoma, as an adjunct to α-adrenergic blocking agents.a b Initiate therapy with an α-adrenergic blocking agent prior to treatment of pheochromocytoma.b (See Pheochromocytoma under Cautions.)

Thyrotoxicosis

Short-term (2–4 weeks) adjunctive therapy of tachycardia and supraventricular arrhythmias in patients with thyrotoxicosis when these symptoms are distressful or hazardous, or when immediate therapy is necessary.a

Vascular Headache

Prophylaxis of common migraine headache; not recommended for the treatment of a migraine attack that has already started.b

MI

Secondary prevention following acute MI to reduce the risk of cardiovascular mortality.245 248 249 261 527 602

Administration within 5–21 days following MI associated with reductions in overall and cardiovascular mortality.602 a

Experts recommend β-blocker therapy in all patients with left ventricular systolic dysfunction and prior MI; a β-blocker with proven mortality benefit (bisoprolol, carvedilol, or metoprolol succinate) is preferred.525 Although benefits of long-term β-blockade in patients with normal left ventricular function are less well established, experts recommend continued β-blocker therapy for at least 3 years in such patients.525

Essential Tremor

Management of essential (familial, hereditary) tremor.201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229

Not indicated for tremor associated with Parkinsonism.b

Propranolol Dosage and Administration

General

BP Monitoring and Treatment Goals

Administration

Administer orally or IV.338 700 701 b

Individualize dosage according to patient response.a

Oral Administration

Administer conventional tablets in divided doses before meals and at bedtime.a

Administer extended-release capsules once daily.a c

Extended-release capsules produce lower blood concentrations than conventional tablets; do not substitute on a mg-for-mg basis.c Consider dosage retitration when switching from conventional tablets to extended-release capsules, especially to maintain effectiveness at the end of the dosing interval.c

Dilute oral concentrate solution with water, juice, or carbonated beverages or mix with semisolid foods (e.g., applesauce, puddings) just prior to administration.a

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Monitor ECG and central venous pressure carefully during IV administration.201

Replace IV therapy with oral therapy as soon as possible.b

Rate of Administration

Administer by slow IV injection at a rate not >1 mg/minute.b

Dosage

Available as propranolol hydrochloride; dosage expressed in terms of the salt.600 601 602 b

If long-term therapy is to be discontinued, reduce dosage gradually over a period of about 2 weeks.a (See Abrupt Withdrawal of Therapy under Cautions.)

Pediatric Patients

Hypertension
Oral

Some experts have recommended an initial dosage of 1–2 mg/kg daily given in 2 or 3 divided doses as an immediate-release formulation.335 Increase dosage as necessary up to a maximum dosage of 4 mg/kg (up to 640 mg) daily given in 2 or 3 divided doses.335

Extended-release formulation may be administered once daily.335

Cardiac Arrhythmias
Oral

Initially, 1.5–2 mg/kg daily; titrate upward as necessary to 16 mg/kg daily in 4 divided doses to control the arrhythmia.231 232

Dosages >4 mg/kg daily may be necessary for the management of supraventricular tachyarrhythmias.231 232

IV

10–20 mcg/kg infused over 10 minutes has been recommended.a

Thyrotoxicosis
Treatment of Tachyarrhythmias in Neonates with Thyrotoxicosis
Oral

2 mg/kg daily in 2–4 divided doses has been used.a Higher dosages occasionally may be needed.a

Adults

Hypertension
Propranolol Therapy
Oral

Conventional tablets or oral solution: Initially, 40 mg twice daily, either alone or in combination with a diuretic.201 602 Manufacturers state usual effective dosage is 120–240 mg daily.201 Some experts state usual dosage range is 80–160 mg daily, given in 2 divided doses.1200 If satisfactory BP response is not maintained throughout the day, larger doses or administration in 3 divided doses daily may be required.201

Extended-release capsules: Initially, 80 mg once daily, either alone or in combination with a diuretic.314 600 601 Manufacturers state usual effective dosage is 120–160 mg once daily.314 Some experts state usual dosage range is 80–160 mg once daily.1200 However, manufacturer of Innopran XL states that dosages >120 mg once daily do not provide additional hypotensive effects.600

Full hypotensive effect usually evident within 2–3 weeks, but timing is variable.600

Propranolol/Hydrochlorothiazide Fixed-combination Therapy
Oral

Administer in 2 divided doses daily (up to 160 mg of propranolol hydrochloride and 50 mg of hydrochlorothiazide total daily dosage).c

Combination preparation is inappropriate with propranolol hydrochloride dosages >160 mg daily due to excessive dosage of the thiazide component.323 May gradually add another antihypertensive agent when necessary using half of the usual initial dosage to avoid an excessive decrease in BP.323

Initial use of fixed-combination preparations is not recommended; adjust by administering each drug separately, then use the fixed combination if the optimum maintenance dosage corresponds to the drug dosages in the combination preparation.a

Chronic Stable Angina
Oral

Conventional tablets or oral solution: Usual dosage is 80–320 mg daily in 2–4 divided doses.201 315 Dosages exceeding 320 mg daily have been recommended when there is only a partial response to usual dosage.a

Extended-release capsules: Initially, 80 mg daily.314 Gradually increase dosage at 3- to 7-day intervals as needed to control symptoms.314 Optimum response usually occurs at 160 mg daily, but there is wide variation in response.314

Periodically reevaluate chronic therapy for angina to determine need for dosage adjustment or continued therapy.a

Cardiac Arrhythmias
Oral

Conventional tablets or oral solution: usually 10–30 mg 3 or 4 times daily.b

Life-threatening Arrhythmias or Those Occurring during Anesthesia
IV

1–3 mg by slow IV injection.201 If necessary, repeat dose after 2 minutes.201 May administer additional doses at intervals of ≥4 hours until desired response is obtained.201

SVT (e.g., Atrial Flutter, Junctional Tachycardia, PSVT, Atrial Tachycardia)
IV

Some experts recommend initial dose of 1 mg over 1 minute; may repeat at 2-minute intervals up to 3 doses.700

Oral

Usual maintenance dosage: 40–160 mg daily in single (with long-acting preparations) or divided doses.700

Atrial Fibrillation
IV

Experts recommend initial dose of 1 mg over 1 minute; may repeat at 2-minute intervals up to 3 doses.701

Oral

Usual maintenance dosage: 40–160 mg daily in divided doses.701

Hypertrophic Subaortic Stenosis
Oral

Conventional tablets or oral solution: 20–40 mg 3 or 4 times daily.201 314 315

Extended-release capsules: 80–160 mg once daily.201 314 315

Pheochromocytoma
Prior to Surgery
Oral

Conventional tablets or oral solution: 60 mg daily in divided doses (in conjunction with an α-adrenergic blocking agent) for 3 days prior to surgery.201 315 (See Pheochromocytoma under Cautions.)

Adjunctive Treatment for Inoperable Pheochromocytoma.
Oral

30 mg daily in divided doses (in conjunction with an α-adrenergic blocker).201 315 (See Pheochromocytoma under Cautions.)

Vascular Headache
Prevention of Common Migraine
Oral

Conventional tablets or oral solution: initially, 80 mg daily in divided doses.201 314 315

Extended-release capsules: 80 mg once daily.201 314 315

Gradually increase dosage to achieve optimum response; usual effective dosage is 80–240 mg daily.201 314 315 326

Discontinue if response is inadequate after 4–6 weeks; gradual withdrawal over several weeks may be advisable.201 314 315

MI
Mortality Reduction after Acute MI
Oral

Conventional tablets or oral solution: 180–240 mg daily in divided doses; in the study demonstrating mortality benefit with propranolol, the drug was initiated 5–21 days after infarction.201 315 602 Higher dosage may be necessary for patients with coexisting conditions (e.g., angina, hypertension).201 315

Administered in 3–4 divided doses daily in clinical studies, but twice-daily dosing also may be adequate.201

Optimal duration of therapy for secondary prevention remains to be clearly established.802 804 Experts generally recommend long-term therapy in post-MI patients with left ventricular systolic dysfunction, and at least 3 years of therapy in those with normal left ventricular function.525 802 804 1101

Essential Tremor
Routine Therapy
Oral

Conventional tablets: Initially, 40 mg twice daily.201 229

Response is variable and dosage must be individualized; optimal suppression of tremor usually occurs with 120–320 mg daily in 3 divided doses.201 202 203 204 205 207 208 211 213 214 215 216 219 220 221 228 229

Complete suppression of tremor rarely is achieved;205 206 207 214 215 220 225 226 dosages exceeding 320 mg daily may not provide substantial added benefit but are associated with an increased risk of adverse effects.205 209 221

Extended-release capsules: Usual dosages administered once daily each morning appear to be at least as effective as equivalent dosages of conventional tablets administered in divided doses daily.216

Intermittent Therapy
Oral

Conventional tablets: 80–120 mg as a single dose 1–3 hours before planned activity or anticipated stress associated with tremor.202 208 211 227

Prescribing Limits

Pediatric Patients

Hypertension
Oral

Some experts have recommended a maximum dosage of 4 mg/kg (up to 640 mg) daily.335

Adults

Chronic Stable Angina
Oral

320 mg daily; some clinicians recommend higher dosage if there is only a partial response to usual dosage.a

MI
Oral

240 mg daily.201 315

Essential Tremor
Oral

320 mg daily; higher dosages do not provide substantial added benefit and are associated with an increased risk of adverse effects.205 209 221

Special Populations

Hepatic Impairment

Use with caution.b

Renal Impairment

Dosage adjustments not required.a Use with caution.b

Geriatric Patients

Use caution in dosage selection; initiate therapy at low end of dosage range.b

Detailed Propranolol dosage information

Cautions for Propranolol

Contraindications

Warnings/Precautions

Warnings

Heart Failure

Possible precipitation of heart failure.b

Avoid use in patients with overt heart failure;b may use cautiously in patients with inadequate myocardial function and, if necessary, in patients with well-compensated heart failure (e.g., those controlled with heart glycosides and/or diuretics).b a Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending heart failure occur; if heart failure continues, discontinue therapy, gradually if possible.b

Possible decreased exercise tolerance in patients with left ventricular dysfunction.a

Abrupt Withdrawal of Therapy

Abrupt withdrawal of propranolol is not recommended as it may exacerbate angina symptoms or precipitate MI in patients with CAD.a b Gradually decrease dosage over about 2 weeks and monitor patients carefully.b a If exacerbation of angina occurs or acute coronary insufficiency develops, reinstitute therapy promptly, at least temporarily, and initiate appropriate measures for the management of unstable angina.b

Bronchospastic Disease

Possible inhibition of bronchodilation produced by endogenous catecholamines.b Possible increased airway resistance and bronchospasm, particularly in patients with a history of asthma.a

Use with caution in patients with a history of nonallergic bronchospasm (e.g., chronic bronchitis, emphysema).b Use not recommended in patients with bronchial asthma.b (See Contraindications under Cautions.)

Major Surgery

Possible increased risks associated with general anesthesia (e.g., severe hypotension, difficulty restarting or maintaining heart beat) due to decreased ability of the heart to respond to reflex β-adrenergic stimuli.b a Use with extreme caution for management of arrhythmias occurring during anesthesia with myocardial depressant anesthetics.a

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia, palpitation, BP changes, tremor).305 b Possible hypoglycemia, especially in those undergoing dialysis, prolonged fasting, or severe exercise regimens.305 314

Use with caution in patients with diabetes mellitus.a

Thyrotoxicosis

Signs of hyperthyroidism may be masked.b Possible thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.b a Possible altered thyroid function test results.b a

Bradycardia

Possible bradycardia, occasionally severe and accompanied by hypotension, syncope, shock, or angina.b a Severe bradycardia requiring a demand pacemaker has occurred in patients with Wolff-Parkinson-White syndrome.b Treat severe bradycardia with IM or IV atropine sulfate.a If response is inadequate, consider cautious administration of IV isoproterenol.a

Possible depressed SA node automaticity; use with caution in patients with sinus node dysfunction.a

AV Block

Possible intensification of AV block, AV dissociation, AV conduction delays, complete heart block, or cardiac arrest, especially in patients with preexisting heart block caused by digitalis or other factors.a

Pheochromocytoma

To prevent severe hypertension, institute α-adrenergic blocking agent therapy prior to the use of propranolol and continue during propranolol therapy.b

General Precautions

History of Anaphylactic Reactions

Possible increased reactivity to a variety of allergens; patients may be unresponsive to usual doses of epinephrine used to treat anaphylactic reactions.201 314

Ocular Effects

May reduce IOP; may interfere with glaucoma screening tests.338 IOP may increase upon drug withdrawal.338

Myasthenia Gravis

Myasthenic condition (e.g., ptosis, weakness of limbs, and double vision) reported rarely with propranolol; use may be contraindicated in patients with myasthenia gravis.a

Other Precautions

Shares the toxic potentials of β-blockers; observe usual precautions of these agents.a

When used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with thiazide diuretics.a

Specific Populations

Pregnancy

Category C.b c d

Lactation

Distributed into milk.b c d Use with caution.b c d

Pediatric Use

Efficacy and adverse effect profiles in children generally similar to such profiles in adults.201 Bioavailability may be increased in children with Down’s syndrome.201 Safety and efficacy of extended-release capsules, oral solution, and injection not established in children.a

Geriatric Use

Insufficient evidence in patients ≥65 years of age to determine whether geriatric patients respond differently than younger patients.a Select dosage with caution, usually initiating therapy at the low end of the dosage range because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.a

Hepatic Impairment

Use with caution;b assess hepatic function prior to and periodically during prolonged therapy.a

Renal Impairment

Use with caution;b assess renal function prior to and periodically during prolonged therapy.a

Common Adverse Effects

Bradycardia, nausea, vomiting, diarrhea, epigastric distress, abdominal cramping, constipation, flatulence.b a

Drug Interactions

Specific Drugs

Drug

Interaction

Comments

Antipsychotic agents (e.g., phenothiazines)

Possible additive hypotensive effect, especially with large doses of phenothiazinesa

Chlorpromazine

Possible decreased propranolol clearancea

Thioridazine

Possible decreased thioridazine metabolism.310

Possible increased risk of serious, potentially fatal cardiac arrhythmias (e.g., torsades de pointes)310

Concomitant use contraindicated310

Haloperidol

Possible hypotension and cardiac arresta

Fluoxetine

Possible decreased propranolol metabolism;272 273 complete heart block reported272 273

Caution recommended with concomitant use and in those with impaired cardiac conduction272

Sympathomimetic agents

Possible antagonism of β-adrenergic stimulating effects;a very large doses of isoproterenol may be needed to overcome β-adrenergic blocking effectsa

Administer epinephrine with caution; decreased pulse rate with first- and second-degree heart block may occura

Drugs with anticholinergic effects

Possible antagonism of cardiac β-adrenergic blocking effectsa

Diuretics

Possible increased hypotensive effecta

Careful dosage adjustments recommendeda

Reserpine

Possible additive effectsa

Antiarrhythmic drugs (lidocaine, phenytoin, procainamide, quinidine, verapamil)

Possible additive or antagonistic cardiac effects and additive toxic effectsa

Verapamil

Serious adverse reactions reported rarely with concomitant IV verapamil, especially in patients with severe cardiomyopathy, CHF, or recent MIa

Other cardiovascular drugs (e.g., cardiac glycosides, nondihydropyridine calcium-channel blocking agents)

Possible additive negative effects on SA or AV nodal conductiona

Neuromuscular blocking agents

Possible increased effects of neuromuscular blocking agentsa

Administer with caution to patients receiving or recovering from the effects of neuromuscular blocking agentsa

Antidiabetic agents

Possible altered antidiabetic responsea

Close monitoring recommendeda

Ergot alkaloids

Possible additive peripheral vasoconstrictiona

Use concomitantly with cautiona

Cimetidine

Possible decreased propranolol clearancea

Monitor for signs and symptoms of increased β-adrenergic blocking activitya

Antacids

Possible decreased propranolol absorption201 235 236 237

Need to avoid concomitant use or stagger dosing of an aluminum hydroxide antacid has not been fully elucidated;237 238 consider increasing propranolol dosage if interaction suspected235 237

Levodopa

Possible decreased hypotensive and positive inotropic effects of levodopaa

NSAIAs

Possible decreased hypotensive effects of propranolola

Theophylline

Possible decreased theophylline clearance.a

Possible decreased theophylline-induced bronchodilationa
Propranolol drug interactions (more detail)

Propranolol Pharmacokinetics

Absorption

Bioavailability

Oral absorption almost complete.a

Bioavailabilities of conventional tablet and oral solution reportedly equivalent in adults.a

Oral bioavailability may be increased in children with Down’s syndrome.a

Onset

Conventional oral tablets: peak effect in 1–1.5 hours.b

Plasma Concentrations

100–150 ng/mL with considerable interpatient variation; 100 ng/mL generally represents high degree of β-blockade.a

Distribution

Extent

Widely distributed into body tissues, including lungs, liver, kidneys, and heart.a Portion of orally administered dose immediately bound by liver.b

Crosses blood-brain barrier.a

Crosses placenta and is distributed into milk.a

Plasma Protein Binding

>90% over a wide range of blood concentrations.a

Elimination

Metabolism

Almost completely metabolized in the liver.a

Elimination Route

Excreted principally in urine; at least 8 metabolites have been identified.a

1–4% of an oral or IV dose of the drug appears in feces as unchanged drug and metabolites.a

Half-life

IV: 10 minutes (initial phase), 2.3 hours (terminal phase).b

Conventional oral tablets: about 4 hours.b

3.4–6 hours with chronic administration of usual therapeutic doses; 2–3 hours after single dose.a

Extended-release capsules: apparent half-life about 10 hours.c

Special Populations

In patients with severely impaired renal function, a compensatory increase in fecal excretion of propranolol occurs.a Propranolol apparently not substantially removed by hemodialysis.a

Stability

Storage

Oral

Capsules

Tight, light-resistant containers at 20–25°C; protect from moisture, freezing or excessive heat.c

Tablets

10, 60, and 80 mg: Tight containers at 20–25°C.b

20 and 40 mg: Tight, light-resistant containers at 20–25°C.b

Tablets (Propranolol Hydrochloride and Hydrochlorothiazide)

Tight containers at about 25°C; protect from moisture, freezing or excessive heat.d

Solution and Solution Concentrate

Tight, light-resistant containers at 20–25°C.a

Maximum stability at pH 3, rapidly decomposes at alkaline pH.a

Decomposition in aqueous solution is accompanied by lowered pH and discoloration.a

Parenteral

Injection

20–25°C; Protect from freezing or excessive heat.b

Compatibility

Parenteral

Solution CompatibilityHID

Compatible

Dextrose 5% in sodium chloride 0.45 or 0.9%

Dextrose 5% in water

Ringer’s injection, lactated

Sodium chloride 0.45 or 0.9%
Drug Compatibility
Admixture CompatibilityHID

Compatible

Dobutamine HCl

Verapamil HCl
Y-Site CompatibilityHID

Compatible

Alteplase

Fenoldopam mesylate

Heparin sodium

Hydrocortisone sodium succinate

Linezolid

Meperidine HCl

Milrinone lactate

Morphine sulfate

Nesiritide

Potassium chloride

Propofol

Tacrolimus

Tirofiban HCl

Incompatible

Amphotericin B cholesteryl sulfate complex

Actions

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Propranolol Hydrochloride

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules, extended-release

60 mg

Inderal LA

Ani Pharms

80 mg

Inderal LA

Ani Pharms

Innopran XL

Ani Pharms

120 mg

Inderal LA

Ani Pharms

Innopran XL

Ani Pharms

160 mg

Inderal LA

Ani Pharms

Solution

20 mg/5 mL*

Propranolol Hydrochloride Solution

40 mg/5 mL*

Propranolol Hydrochloride Solution

Tablets

10 mg*

Propranolol Hydrochloride Tablets

20 mg*

Propranolol Hydrochloride Tablets

40 mg*

Propranolol Hydrochloride Tablets

60 mg*

Propranolol Hydrochloride Tablets

80 mg*

Propranolol Hydrochloride Tablets

Parenteral

Injection

1 mg/mL*

Propranolol Hydrochloride Injection

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Propranolol Hydrochloride and Hydrochlorothiazide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

40 mg Propranolol Hydrochloride and Hydrochlorothiazide 25 mg*

Propranolol Hydrochloride and hydroCHLOROthiazide Tablets

80 mg Propranolol Hydrochloride and Hydrochlorothiazide 25 mg*

Propranolol Hydrochloride and hydroCHLOROthiazide Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions April 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

201. Ayerst Laboratories Inc. Inderal (propranolol hydrochloride) tablets prescribing information. Philadelphia, PA; 2002 Jan.

202. Findley LJ. The pharmacological management of essential tremor. Clin Neuropharmacol. 1986; 9:S61-75. http://www.ncbi.nlm.nih.gov/pubmed/2885088?dopt=AbstractPlus

203. Larsen AT, Teravainen H. β1 versus nonselective blockade in therapy of essential tremor. Adv Neurol. 1983; 37:247-51. http://www.ncbi.nlm.nih.gov/pubmed/6344590?dopt=AbstractPlus

204. Calzetti S, Findley LJ, Perucca E et al. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. J Neurol Neurosurg Psychiatry. 1982; 45:893-7. http://www.ncbi.nlm.nih.gov/pubmed/6815306?dopt=AbstractPlus

205. Koller WC. Dose-response relationship of propranolol in the treatment of essential tremor. Arch Neurol. 1986; 43:42-3. http://www.ncbi.nlm.nih.gov/pubmed/3942513?dopt=AbstractPlus

206. Young RR. Propranolol in essential tremor. Neurology. 1985; 35:445-6. http://www.ncbi.nlm.nih.gov/pubmed/3974911?dopt=AbstractPlus

207. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986; 36:1001-4. http://www.ncbi.nlm.nih.gov/pubmed/2940473?dopt=AbstractPlus

208. Koller WC, Royse VL. Time course of a single oral dose of propranolol in essential tremor. Neurology. 1985; 35:1494-8. http://www.ncbi.nlm.nih.gov/pubmed/4033931?dopt=AbstractPlus

209. Koller WC. Treatment of essential tremor—further comment. Ann Neurol. 1985; 18:369. http://www.ncbi.nlm.nih.gov/pubmed/3931542?dopt=AbstractPlus

210. Koller WC, Royse VL. Time course of a single oral dose of propranolol in essential tremor. Neurology. 1986; 36:876. http://www.ncbi.nlm.nih.gov/pubmed/3703304?dopt=AbstractPlus

211. Findley LJ, Cleeves L. Tremor. BMJ. 1984; 288:1536-7. http://www.ncbi.nlm.nih.gov/pubmed/6426631?dopt=AbstractPlus

212. Findley LJ, Cleeves L. Beta adrenoreceptor antagonists in essential tremor. Lancet. 1984; 1:856-7.

213. Murray TJ. Long-term therapy of essential tremor with propranolol. Can Med Assoc J. 1976; 115:892-4. http://www.ncbi.nlm.nih.gov/pubmed/791468?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1879108&blobtype=pdf

214. Winkler GF, Young RR. Efficacy of chronic propranolol therapy in action tremors of the familial senile or essential varieties. N Engl J Med. 1974; 290:984-8. http://www.ncbi.nlm.nih.gov/pubmed/4594525?dopt=AbstractPlus

215. Tolosa ES, Loewenson RB. Essential tremor: treatment with propranolol. Neurology. 1975; 25:1041-4. http://www.ncbi.nlm.nih.gov/pubmed/1237822?dopt=AbstractPlus

216. Koller WC. Long-acting propranolol in essential tremor. Neurology. 1985; 35:108-10. http://www.ncbi.nlm.nih.gov/pubmed/3965982?dopt=AbstractPlus

217. Koller W, Graner D, Mlcoch A. Essential voice tremor: treatment with propranolol. Neurology. 1985; 35:106-8. http://www.ncbi.nlm.nih.gov/pubmed/3880874?dopt=AbstractPlus

218. Baruzzi A, Procaccianti G, Martinelli P et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology. 1983; 33:296-300. http://www.ncbi.nlm.nih.gov/pubmed/6338416?dopt=AbstractPlus

219. Koller WC. Propranolol therapy for essential tremor of the head. Neurology. 1984; 34:1077-9. http://www.ncbi.nlm.nih.gov/pubmed/6379505?dopt=AbstractPlus

220. Teravainen H, Fogelholm R, Larsen A. Effect of propranolol on essential tremor. Neurology. 1976; 26:27-30. http://www.ncbi.nlm.nih.gov/pubmed/1107883?dopt=AbstractPlus

221. Koller WC. Dose-response relationship of propranolol in essential tremor. Neurology. 1985; 35(Suppl 1):160.

222. Cleeves L, Findley LJ. Time course of a single oral dose of propranolol in essential tremor. Neurology. 1986; 36:876. http://www.ncbi.nlm.nih.gov/pubmed/3703304?dopt=AbstractPlus

223. Calzetti S, Findley LJ, Perucca E et al. Metoprolol in essential tremor. Lancet. 1981; 2:1227. http://www.ncbi.nlm.nih.gov/pubmed/6118649?dopt=AbstractPlus

224. Calzetti S, Findley LJ, Perucca S et al. The response of essential tremor to propranolol: evaluation of clinical variables governing its efficacy on prolonged administration. J Neurol Neurosurg Psychiatry. 1983; 46:393-8. http://www.ncbi.nlm.nih.gov/pubmed/6101174?dopt=AbstractPlus

225. Findley LJ, Calzetti S, Gresty MA et al. Amplitude of benign essential tremor and response to propranolol. Lancet. 1981; 2:479-80. http://www.ncbi.nlm.nih.gov/pubmed/6115243?dopt=AbstractPlus

226. Koller WC. Propranolol in essential tremor. Neurology. 1985; 35:446. http://www.ncbi.nlm.nih.gov/pubmed/3974912?dopt=AbstractPlus

227. Calzetti S, Findley LJ, Gresty MA et al. Effect of a single oral dose of propranolol on essential tremor: a double-blind controlled study. Ann Neurol. 1983; 13:165-71. http://www.ncbi.nlm.nih.gov/pubmed/6338809?dopt=AbstractPlus

228. Huttunen J, Teravainen H, Larsen TA. Beta adrenoreceptor antagonists in essential tremor. Lancet. 1984; 1:57.

229. Wilson JF, Marshall RW, Richens A. Essential tremor: treatment with beta-adrenoceptor blocking drugs. In: Findley LJ, Capildea R. Movement disorders: tremor. London: Macmillan; 1984:245-60.

230. National Heart, Lung, and Blood Institute Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children—1987. Pediatrics. 1987; 79:1-25. http://www.ncbi.nlm.nih.gov/pubmed/3797155?dopt=AbstractPlus

231. Gillette PC. Advances in the diagnosis and treatment of tachydysrhythmias in children. Am Heart J. 1981; 102:111-20. http://www.ncbi.nlm.nih.gov/pubmed/7246397?dopt=AbstractPlus

232. Pickoff AS, Zies L, Ferrer PL et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr. 1979; 94:144-6. http://www.ncbi.nlm.nih.gov/pubmed/758396?dopt=AbstractPlus

233. Cohen SN, Kauffman RE, Strebel L. Appendix: Drugs. In: Behrman RE, Vaughan VC, eds. Nelson textbook of pediatrics. 13th ed. Philadelphia: W. B. Saunders Company; 1987: 1520-34.

234. Cleeves L, Findley LJ. Beta-adrenoreceptor mechanisms in essential tremor: a comparative single dose study of the effect of non-selective and a beta-2 selective adrenoreceptor antagonist. J Neurol Neurosurg Psychiatry. 1984; 47:976-82. http://www.ncbi.nlm.nih.gov/pubmed/6148382?dopt=AbstractPlus

235. Dobbs JH, Skoutakis VA, Acchiardo SR et al. Effects of aluminum hydroxide on the absorption of propranolol. Curr Ther Res. 1977; 21:887-92.

236. Remon JP, Belpaire F, Van Severen R et al. Interaction of antacids with antiarrhythmics. V. Effect of aluminum hydroxide and magnesium oxide on the bioavailability of quinidine, procainamide and propranolol in dogs. Arzneimittelforschung. 1983; 33:117-20. http://www.ncbi.nlm.nih.gov/pubmed/6681962?dopt=AbstractPlus

237. Mangini RJ, ed. Drug interactions facts. St. Louis: JB Lippincott Co; 1986(Apr):105.

238. Hong CY, Hu SC, Lin SJ et al. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Pharmacol Ther Toxicol. 1985; 23:244-6.

239. McElnay JC, Temple DJ. The use of buccal partitioning as a model to examine the effects of aluminum hydroxide gel on the absorption of propranolol. Br J Clin Pharmacol. 1982; 13:399-403. http://www.ncbi.nlm.nih.gov/pubmed/7059441?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1402112&blobtype=pdf

240. Potter DE, Schambelan M, Salvatierra O et al. Treatment of high-renin hypertension with propranolol in children after renal transplantation. J Pediatr. 1977; 90:307-11. http://www.ncbi.nlm.nih.gov/pubmed/318685?dopt=AbstractPlus

241. Ozsoylu S, Kocak N, Yuce A. Propranolol therapy for portal hypertension in children. J Pediatr. 1985; 106:317-21. http://www.ncbi.nlm.nih.gov/pubmed/3968624?dopt=AbstractPlus

242. Pennisi AJ, Takahashi M, Bernstein BH et al. Minoxidil therapy in children with severe hypertension. J Pediatr. 1977; 90:813-9. http://www.ncbi.nlm.nih.gov/pubmed/323442?dopt=AbstractPlus

243. Park MK. Pediatric cardiology for practitioners. Chicago, IL: Year Book Medical Publishers; 1984:284.

245. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease: I. Treatments following myocardial infarction. JAMA. 1988; 260:2088-93. http://www.ncbi.nlm.nih.gov/pubmed/2901501?dopt=AbstractPlus

246. American College of Cardiology and American Heart Association. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Early Management of Patients with Acute Myocardial Infarction). Circulation. 1990; 82:664-707. http://www.ncbi.nlm.nih.gov/pubmed/2197021?dopt=AbstractPlus

247. Roque F, Amuchastegui LM, Lopez Morillos MA et al. The TIARA Study Group. Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction. Circulation. 1987; 76:610-7. http://www.ncbi.nlm.nih.gov/pubmed/3304706?dopt=AbstractPlus

248. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med. 1988; 319:152-7. http://www.ncbi.nlm.nih.gov/pubmed/2898733?dopt=AbstractPlus

249. Yusuf S, Peto R, Lewis J et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985; 27:335-71. http://www.ncbi.nlm.nih.gov/pubmed/2858114?dopt=AbstractPlus

250. Yusuf S, Sleight P, Held P et al. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990; 82(Suppl 11):11-117-34.

251. Held P, Yusuf S. Early intravenous beta-blockade in acute myocardial infarction. Cardiology. 1989; 76:132-43. http://www.ncbi.nlm.nih.gov/pubmed/2568179?dopt=AbstractPlus

252. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985; 313:1055-8. http://www.ncbi.nlm.nih.gov/pubmed/2864634?dopt=AbstractPlus

253. Pedersen TR for the Norwegian Multicenter Study Group. The Norwegian multicenter study of timolol after myocardial infarction. Circulation. 1983; 67(Suppl I):I-49-53.

254. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J. 1988; 9:8-16.

255. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA. 1982; 247:1707-14. http://www.ncbi.nlm.nih.gov/pubmed/7038157?dopt=AbstractPlus

256. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981; 304:801-7. http://www.ncbi.nlm.nih.gov/pubmed/7010157?dopt=AbstractPlus

257. Gheorghiade M, Schultz L, Tilley B et al. Effects of propranolol in non-Q-wave acute myocardial infarction in the beta blocker heart attack trial. Am J Cardiol. 1990; 66:129-33. http://www.ncbi.nlm.nih.gov/pubmed/2196771?dopt=AbstractPlus

258. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. Am J Cardiol. 1990; 66:220-22. http://www.ncbi.nlm.nih.gov/pubmed/1973589?dopt=AbstractPlus

259. Griggs TR, Wagner GS, Gettes LS. Beta-adrenergic blocking agents after myocardial infarction: an undocumented need in patients at lowest risk. J Am Coll Cardiol. 1983; 1:1530-3. http://www.ncbi.nlm.nih.gov/pubmed/6133891?dopt=AbstractPlus

260. Pedersen TR for the Norwegian Multicenter Study Group. Six-year follow-up of the Norwegian multicenter study on timolol after myocardial infarction. N Engl J Med. 1986; 314:1052.

261. Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984; 310:830-7. http://www.ncbi.nlm.nih.gov/pubmed/6142420?dopt=AbstractPlus

262. Roberts R, Rogers WJ, Mueller H et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation. 1991; 83:422-37. http://www.ncbi.nlm.nih.gov/pubmed/1671346?dopt=AbstractPlus

263. Reviewers’ comments (personal observations).

265. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52. http://www.ncbi.nlm.nih.gov/pubmed/8422205?dopt=AbstractPlus

266. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: an overview of randomized drug trials in their epidemiological context. Lancet. 1990; 335:827-38. http://www.ncbi.nlm.nih.gov/pubmed/1969567?dopt=AbstractPlus

267. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

268. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335:765-74. http://www.ncbi.nlm.nih.gov/pubmed/1969518?dopt=AbstractPlus

269. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265:3255-64. http://www.ncbi.nlm.nih.gov/pubmed/2046107?dopt=AbstractPlus

270. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-hypertension). Lancet. 1991; 338:1281-5. http://www.ncbi.nlm.nih.gov/pubmed/1682683?dopt=AbstractPlus

271. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992; 304:405-12. http://www.ncbi.nlm.nih.gov/pubmed/1445513?dopt=AbstractPlus

272. Drake WM, Gordon GD. Heart block in a patient on propranolol and fluoxetine. Lancet. 1994; 343:425-6. http://www.ncbi.nlm.nih.gov/pubmed/7905586?dopt=AbstractPlus

273. Beta-adrenergic blocker interactions: fluoxetine (Prozac). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1994:771.

274. National Heart, Lung, and Blood Institute. NHLBI panel reviews safety of calcium channel blockers. Rockville, MD; 1995 Aug 31. Press release.

275. National Heart, Lung, and Blood Institute. New analysis regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Rockville, MD; 1995 Sep 1.

276. Psaty BM, Heckbert SR, Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274:620-5. http://www.ncbi.nlm.nih.gov/pubmed/7637142?dopt=AbstractPlus

277. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation. 1995; 92:1079-82. Editorial.

278. Roche. Posicor (mibefradil hydrochloride) tablets prescribing information. Nutley, NJ; 1997 Dec.

279. Ellison RH. Dear doctor letter regarding appropriate use of Posicor. Nutley, NJ: Roche Laboratories; 1997 Dec.

280. Sidmak Laboratories. Propranolol hydrochloride and hydrochlorothiazide tablets prescribing information. East Hanover, NJ; 1995 Jan.

281. Swislocki A. Insulin resistance and hypertension. Am J Med Sci. 1990; 300:104-15. http://www.ncbi.nlm.nih.gov/pubmed/2206054?dopt=AbstractPlus

282. White J Jr, Harman J, Campbell K. Drug interactions in diabetic patients. Postgrad Med. 1993; 93:131-9.

283. Joseph J, Schuna A. Management of hypertension in the diabetic patient. Clin Pharm. 1990; 9:864-73. http://www.ncbi.nlm.nih.gov/pubmed/2272152?dopt=AbstractPlus

284. Houston M. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 1988; 115:640-56. http://www.ncbi.nlm.nih.gov/pubmed/3278578?dopt=AbstractPlus

285. Hurel S, Taylor R. Drugs and glucose tolerance. Adverse Drug React Bull. 1995; 174:659-62.

286. Holland B, Kaplan N. Propranolol in the treatment of hypertension. N Engl J Med. 1976; 294:930-6. http://www.ncbi.nlm.nih.gov/pubmed/1256484?dopt=AbstractPlus

287. Chan JCN, Cockram CS. Drug-induced disturbances of carbohydrate metabolism. Adv Drug React Toxicol Rev. 1991; 10:1-29.

288. Reviewers’ comments (personal observations) on metformin 68:20.92.

290. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. http://www.ncbi.nlm.nih.gov/pubmed/8622249?dopt=AbstractPlus

291. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. http://www.ncbi.nlm.nih.gov/pubmed/9042847?dopt=AbstractPlus

293. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. http://www.ncbi.nlm.nih.gov/pubmed/9515998?dopt=AbstractPlus

295. Genuth P. United Kingdom prospective diabetes study results are in. J Fam Pract. 1998; 47:(Suppl 5):S27.

297. Watkins PJ. UKPDS: a message of hope and a need for change. Diabet Med. 1998; 15:895-6. http://www.ncbi.nlm.nih.gov/pubmed/9827842?dopt=AbstractPlus

298. Bretzel RG, Voit K, Schatz H et al. The United Kingdom Prospective Diabetes Study (UKPDS): implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 1998; 106:369-72. http://www.ncbi.nlm.nih.gov/pubmed/9831300?dopt=AbstractPlus

299. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. http://www.ncbi.nlm.nih.gov/pubmed/9732338?dopt=AbstractPlus

300. American Diabetes Association. The United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes: what you need to know about the results of a long-term study. Washington, DC; 1998 Sep 15 from American Diabetes Association web site. http://www.dtu.ox.ac.uk/ukpds

301. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317:713-20. http://www.ncbi.nlm.nih.gov/pubmed/9732338?dopt=AbstractPlus

302. Davis TME. United Kingdom Prospective Diabetes Study: the end of the beginning? Med J Aust. 1998; 169:511-2.

304. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: apporaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.

305. Lim PO, MacDonald TM. Antianginal and β-adrenergic blocking drugs. In: Dukes MNG, ed. Meyler’s side effects of drugs. 13th ed. New York: Elsevier/North Holland Inc; 1996:488-535.

306. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000; 342:905-12. http://www.ncbi.nlm.nih.gov/pubmed/10738048?dopt=AbstractPlus

307. Sower JR, Bakris GL. Antihypertensive therapy and the risk of type 2 diabetes mellitus. N Engl J Med. 2000; 342:969-70. http://www.ncbi.nlm.nih.gov/pubmed/10738057?dopt=AbstractPlus

308. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus

309. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus

310. Novartis Pharmaceuticals Corporation. Mellaril, Mellaril-S (thioridazine) tablets, oral solutions, and oral suspensions prescribing information. East Hanover, NJ; 2000 Jun.

311. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus

312. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351:1755-62. http://www.ncbi.nlm.nih.gov/pubmed/9635947?dopt=AbstractPlus

314. Ayerst Laboratories Inc. InderalLA (propranolol hydrochloride) long acting capsules prescribing information. Philadelphia, PA; 2002 Jan 23.

315. Roxane Laboratories. Propranolol hydrochloride oral solution and oral solution concentrate prescribing information. Columbus, OH; 1995 Sept.

320. Williams CL, Hayman LL, Daniels SR et al. Cardiovascular health in childhood: a statement for health professional from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002; 106:143-60. http://www.ncbi.nlm.nih.gov/pubmed/12093785?dopt=AbstractPlus

323. Ayerst Laboratories Inc. Inderide (propranolol hydrochloride and hydrochlorothiazide) tablets prescribing information. Philadelphia, PA; 2001 May 8.

326. Ramadan NM, Silberstein SD, Freitag FG et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. St. Paul, MN; 2001. From the American Academy of Neurology web site. http://www.aan.com

327. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus

328. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-riskhypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus

330. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

332. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

333. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003; 26(Suppl 1):S80-2.

335. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. http://www.ncbi.nlm.nih.gov/pubmed/15286277?dopt=AbstractPlus

336. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus

337. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus

338. Baxter Healthcare Corporation. Propranolol hydrochloride injection prescribing information. Deerfield, IL; 2006.

339. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.

340. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-34. http://www.ncbi.nlm.nih.gov/pubmed/10600?dopt=AbstractPlus

341. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.

342. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8.

343. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. http://www.ncbi.nlm.nih.gov/pubmed/2869400?dopt=AbstractPlus

344. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. http://www.ncbi.nlm.nih.gov/pubmed/2881524?dopt=AbstractPlus

345. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.

346. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.

347. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. http://www.ncbi.nlm.nih.gov/pubmed/6114433?dopt=AbstractPlus

348. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. http://www.ncbi.nlm.nih.gov/pubmed/581782?dopt=AbstractPlus

349. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. http://www.ncbi.nlm.nih.gov/pubmed/2878346?dopt=AbstractPlus

350. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. http://www.ncbi.nlm.nih.gov/pubmed/2883867?dopt=AbstractPlus

351. Clonidine/beta blockers. In: Tatro DS, Olin BR, Hebel SK, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1992 (July):200.

353. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. http://www.ncbi.nlm.nih.gov/pubmed/11937178?dopt=AbstractPlus

354. Carter B for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Personal communication.

400. Link MS, Berkow LC, Kudenchuk PJ et al. Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132(18 Suppl 2):S444-64. http://www.ncbi.nlm.nih.gov/pubmed/26472995?dopt=AbstractPlus

401. Neumar RW, Otto CW, Link MS et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S729-67. http://www.ncbi.nlm.nih.gov/pubmed/20956224?dopt=AbstractPlus

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471. http://www.ncbi.nlm.nih.gov/pubmed/23166211?dopt=AbstractPlus

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327. http://www.ncbi.nlm.nih.gov/pubmed/23741058?dopt=AbstractPlus

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73. http://www.ncbi.nlm.nih.gov/pubmed/22052934?dopt=AbstractPlus

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.ncbi.nlm.nih.gov/pubmed/23247304?dopt=AbstractPlus

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

600. Akrimax Pharmaceuticals. Innopran XL (propranolol hydrochloride) extended-release capsules prescribing information. Cranford, NJ; 2013 Nov.

601. Akrimax Pharmaceuticals. Inderal LA (propranolol hydrochloride) extended-release capsules prescribing information. Cranford, NJ; 2012 Jun.

602. Par Pharmaceutical. Propranolol hydrochloride tablets prescribing information. Chestnut Ridge, NY; 2016 Oct.

603. Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep. 2004; 8:91-5. http://www.ncbi.nlm.nih.gov/pubmed/14980143?dopt=AbstractPlus

700. Page RL, Joglar JA, Caldwell MA et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67:e27-e115. http://www.ncbi.nlm.nih.gov/pubmed/26409259?dopt=AbstractPlus

701. January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64:e1-76. http://www.ncbi.nlm.nih.gov/pubmed/24685669?dopt=AbstractPlus

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134:. http://www.ncbi.nlm.nih.gov/pubmed/27208050?dopt=AbstractPlus

802. Bockstall K, Bangalore S. How long should we continue beta-blockers after MI? 2017 Jan 23. From ACC website. Accessed 2017 May 17. http://www.acc.org/latest-in-cardiology/articles/2017/01/20/09/36/how-long-should-we-continue-beta-blockers-after-mi

804. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it “ok” to discontinue?. Curr Cardiol Rev. 2012; 8:77-84. http://www.ncbi.nlm.nih.gov/pubmed/22845818?dopt=AbstractPlus

1101. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471. http://www.ncbi.nlm.nih.gov/pubmed/23166211?dopt=AbstractPlus

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534?dopt=AbstractPlus

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. http://www.ncbi.nlm.nih.gov/pubmed/28057444?dopt=AbstractPlus

HID. Trissel LA. Handbook on Injectable Drugs. Bethesda, MD: American Society of Health-System Pharmacists.

a. AHFS Drug Information. McEvoy GK, ed. Propranolol. Bethesda, MD: American Society of Health-System Pharmacists.

b. Ayerst Laboratories Inc. Inderal (propranolol hydrochloride) tablets and injection prescribing information. Philadelphia, PA; 2003 Nov.

c. Ayerst Laboratories Inc. Inderal LA (propranolol hydrochloride) long-acting capsules prescribing information. Philadelphia, PA; 2003 Nov.

d. Ayerst Laboratories Inc. Inderide (propranolol hydrochloride and hydrochlorothiazide) tablets prescribing information. Philadelphia, PA; 2003 Nov.

Frequently asked questions

Medical Disclaimer